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Is there a need to optimize 
glycemic control in hemodialyzed 
diabetic patients?
B Feldt-Rasmussen1
The report of Williams et al. gives rise to at least two important 
questions regarding diabetic patients on maintenance hemodialysis: 
(1) Does glycemic control play a significant role? (2) Is HbA1c a reliable 
measure of glycemic control? These questions are discussed. It is 
recommended that you treat ESRD patients with diabetes according to 
guidelines given for patients without ESRD.
Kidney International (2006) 70, 1392–1394. doi:10.1038/sj.ki.5001886
Th is month, Williams et al.1 (this issue) 
publish an interesting analysis of primary 
data on glycemic control and survival 
of diabetic patients from a large United 
States end-stage renal disease (ESRD) 
database. Patients were drawn from 
among 76 178 ESRD patients treated 
with hemodialysis at Fresenius Medical 
Care, North America, between 1 Octo-
ber and 31 December 2002. Among the 
many interesting results, I found three 
to be of particular interest. First, only a 
weak correlation between hemoglobin 
A1c (HbA1c) and random glucose values 
was observed. Second, the mean HbA1c 
among all type I and type II diabetic 
patients was very good, 6.77%, which is 
lower than normally observed in groups 
of diabetic patients without ESRD. 
Th ird, there was no correlation between 
HbA1c and survival at 12 months. Th is 
raises at least two important questions: 
(1) Does glycemic control play any 
signifi cant role in diabetic patients on 
maintenance hemodialysis? (2) Is HbA1c 
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A key question is whether endog-
enous protease nexin-1 modulates ENaC 
activity in the distal nephron. To begin 
to address this question, Wakida et al.8 
used small interfering RNA to partially 
knock down protease nexin-1 expression 
in the M1 mouse cortical collecting duct 
cell line. Th is was associated with a 60% 
increase in amiloride-sensitive equiva-
lent short circuit current, suggesting 
that endogenous protease nexin-1 has a 
role in modulating ENaC activity in M1 
cells. Furthermore, aldosterone reduced 
the expression of endogenous protease 
nexin-1 in M1 cells.
Volume depletion and aldosterone 
administration are associated with an 
increase in the proteolytic processing of 
ENaC subunits in rodent kidney.10,11 It 
has been proposed that an increase in the 
residency time of channels at the plasma 
membrane in response to aldosterone may 
contribute to the increase in ENaC subunit 
proteolysis, as non-cleaved channels at the 
plasma membrane will have more time to 
be processed by proteases.12 Altering the 
protease/protease inhibitor balance may 
also contribute to the increase in ENaC 
subunit proteolysis observed with volume 
depletion and aldosterone administra-
tion.13 Recent studies in airway epithelia 
are consistent with the notion that the rel-
ative protease/protease inhibitor balance 
may have an important role in determin-
ing the extent of proteolytic processing 
and activity of ENaCs.14 It is clear that 
the regulation of ENaCs by proteases is 
becoming an increasingly complex story.
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a reliable measure of glycemic control in 
these patients?
Glycemic control and development 
and progression of diabetic complica-
tions in patients without end-stage 
renal disease
Since the publication of two landmark 
studies, the Diabetes Control and Com-
plication Trial (DCCT) and the United 
Kingdom Prospective Diabetes Study 
(UKPDS), the importance of tight gly-
cemic control with HbA1c values less 
than 7% has not been challenged.2,3 Th e 
DCCT showed that intensive diabetes 
therapy delayed the onset and slowed the 
progression of retinopathy, nephropathy, 
and neuropathy in type I diabetic patients. 
Only seven subjects in the entire study 
developed urinary albumin excretion 
rates in the range of clinical diabetic neph-
ropathy, so the study was not powered to 
detect eff ects on progression to ESRD. 
Th e indications were, however, that such 
an eff ect could be anticipated.2 In a fol-
low-up study, long-term benefi cial eff ects 
on development of cardiovascular disease 
were also demonstrated.4 In the UKPDS, 
which studied type II diabetic patients, 
glycemic control also played an important 
role in reducing the risk of microvascular 
complications.4 In a more advanced stage 
of renal disease, it was shown that poor 
pre-dialysis glycemic control is a predic-
tor of mortality in type II diabetic patients 
on maintenance hemodialysis.5 Bearing 
these results in mind, it is disappointing 
that only a few minor studies have been 
able also to demonstrate benefi cial eff ects 
of improved glycemic control in ESRD 
patients.2,6 More comprehensive stud-
ies, such as that of Williams et al.,1 fi nd 
no eff ect at all. Th is report raises serious 
questions about the existence of any such 
association, when it cannot be confi rmed 
in an analysis of a clinical database includ-
ing more than 23 000 patients. Should this 
discourage attempts to aim for low HbA1c 
values in ESRD patients? Many clinicians 
would probably fi nd a point in arguing 
that regardless of the lack of documented 
eff ects on survival, there still is good rea-
son to improve glycemic control. Aft er all, 
it is likely that such a treatment strategy 
would be benefi cial in order to prevent 
progression of other diabetic complica-
tions such as retinopathy, neuropathy, and 
macrovascular disease.
Hemoglobin A1c: does it reflect mean 
blood glucose in diabetic patients on 
hemodialysis?
Are there any suffi  ciently validated meth-
ods for monitoring the glycemic level in 
ESRD patients? Clinical treatment of dia-
betic patients, as well as studies of eff ects 
of improved glycemic control, obviously 
relies on proper methods to monitor 
the glycemic level over longer periods 
of time. Is HbA1c a reliable method in 
patients with ESRD? Indications are that 
it is not.1,7,8 Signifi cant problems exist in 
demonstrating a clinically relevant associa-
tion between HbA1c and glycemic levels 
in patients on peritoneal dialysis,7 as well 
as in patients on maintenance hemodi-
alysis.1,8 Th ese problems have, in many 
reports, been neglected or described as 
being of minor importance, leaving the 
impression that there are problems but that 
they can be overcome. Among the argu-
ments is the fact that HbA1c can be reli-
ably measured and provide valid results (of 
HbA1c concentration) for most patients 
with ESRD if an appropriate methodology 
is used. Does this HbA1c value also refl ect 
mean blood glucose over a longer period 
of time? Apparently not. Th us, in the study 
of Williams et al.,1 only a weak correlation 
with mean random glucose was observed 
(R2, 0.37; standard error, 1.36). Th is con-
fi rms previous observations by another 
group reporting a similar poor correla-
tion.8 Th e problem is depicted and clearly 
demonstrated in Figure 1 (from the article 
by Joy et al.8). A mean blood glucose of 
180 mg/dl can be found in the presence 
of an HbA1c level between 6.2% and 9%. 
Furthermore, the HbA1c level may be 
systematically underestimated in patients 
on hemodialysis because of the reduced 
lifespan of the erythrocytes. Although the 
potential risk of underestimating HbA1c 
is still debated, data from the study of Wil-
liams et al.1 suggest that it is a signifi cant 
clinical problem. Take, for instance, the 
mean HbA1c of 6.7% among all diabetic 
patients and of 7.5% among the (few) type 
I diabetic patients observed in the study.1 
These values are surprisingly low and 
prompt one to speculate as to whether the 
diagnosis of diabetes has been correct in 
all patients. Th e UKPDS, which compared 
intensive versus conventional treatment 
in type II diabetic patients, found HbA1c 
values of 7.0% and 7.9%, respectively, and 
the DCCT, which compared the two treat-
ments in type I diabetic patients, found val-
ues of 7.0% and 9.0%, respectively. What 
are the odds that the true level of glycemic 
control in large unselected groups of dia-
betic ESRD patients is better than or almost 
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Figure 1 | Average blood glucose (mg/dl) versus HbA1c (%) in 23 diabetic patients on 
maintenance hemodialysis. SD, standard deviation. Reprinted from American Journal of Kidney 
Diseases, Vol. 39. Joy, MS et al., “Long-term glycemic control measurements in diabetic patients 
receiving hemodialysis,” pp. 297–307, 2002, with permission from National Kidney Foundation, Inc.
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as good as what was observed in the inten-
sive-treatment groups of the UKPDS and 
the DCCT? My guess is that the glycemic 
control in conventionally treated ESRD 
patients should be poor, considering the 
fact that, for all we know, they come from 
a group of patients with poor glycemic con-
trol through their diabetic life.
Apparently, there is a need to recon-
sider the value of HbA1c in patients 
with ESRD.
Cardiovascular morbidity, mortality, gly-
cemic control, and other risk factors
Whereas optimized glycemic control 
undoubtedly plays a major role in pre-
venting progression of microvascular 
complications, it is not the only factor of 
importance. Other factors involved include 
blood pressure level, hypercholesterolemia, 
smoking habits, exercise, and so on. Th is 
was clearly shown in a study of type II 
diabetic patients with microalbuminuria, 
which tested the eff ects of a multifactorial 
intervention consisting of angiotensin-
converting enzyme inhibitors, blood pres-
sure reduction, glycemic control, statins, 
vitamins, weight reduction, and exercise.9 
Th is study demonstrated important clini-
cal eff ects in the intervention group. Th e 
multifactorial pathophysiological mecha-
nisms behind micro- and macrovascular 
complications of diabetes may explain why 
studies of, or intervention against, only one 
risk factor may not show any benefi cial 
eff ects. It is the combined eff ect of mul-
tifactorial intervention that is important. 
Th is may in particular be the case in ESRD 
patients with diabetes, who, in addition to 
diabetes per se, are carrying so many other 
risk factors directly associated with their 
uremic state. Along similar lines, inter-
vention against only one risk factor in the 
4D trial (Die Deutsche Diabetes Dialyse 
Studie) of statins in a population of type II 
diabetic patients on maintenance hemo-
dialysis also failed to show an eff ect.10 So 
apparently there is no eff ect of treatment 
with statins or optimized glycemic control 
in type II diabetic patients on hemodialy-
sis! But would a multifactorial treatment 
approach have revealed a synergy between 
these diff erent treatments?
The introduction of multifactorial 
intervention in all diabetic patients on a 
nationwide basis in Denmark has been 
proven to postpone the development of 
ESRD.11 It is therefore important to intro-
duce and focus on such an approach in 
diabetic patients during their diabetic life, 
long before they reach the stage of ESRD. 
What can we do when these patients 
progress to ESRD? Are there any data 
indicating that, when starting hemodi-
alysis, we should stop all these interven-
tional measures? To my mind, there is no 
good reason to discontinue multifactorial 
intervention in these patients when they 
reach ESRD, including the optimization 
of glycemic control. Th ese eff orts should 
continue despite the fact that the evidence 
so far is not very strong for using any of 
these individual treatment modalities in 
diabetic patients with ESRD.
Final remarks
Williams et al.1 state that more studies 
are needed in chronic kidney disease and 
ESRD patients in order to refi ne evidence-
based recommendations for the appropri-
ate application of tests (such as HbA1c) that 
are currently used to defi ne glycemic con-
trol. I absolutely agree. Th ey also state that 
more studies are needed to determine evi-
dence-based treatment goals for glycemic 
control in this patient population.1 Any 
such study will be very diffi  cult to perform, 
however, and will have to address multi-
factorial interventions. While awaiting the 
results, I will rely on the documentation 
so amply provided by studies of diabetic 
patients in earlier stages of disease and 
recommend that you extend the present 
guidelines to the treatment of patients with 
ESRD. Personally, I would require evidence 
of no eff ect or harmful eff ects before chang-
ing treatment strategies at the time when 
the patients enter ESRD. Th e concept of 
reverse epidemiology in ESRD patients is 
intensely debated at this time. Th e question 
is whether there also is a need for “reverse 
evidence-based medicine.”
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